Neurogene (NGNE) announced the appointment of Christy Shafer as Chief Commercial Officer and the appointment of Christine Mikail, president and CFO, to its Board of Directors. Shafer most recently served as Senior Vice President and General Manager, North America, of Avidity Biosciences.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGNE:
- Compelling Risk‑Reward in Neurogene’s NGN-401: Differentiated Gene Therapy Approach in Rett Syndrome Supports Buy Rating
- 3 Best High-Risk, High-Reward Stocks to Buy Now, According to Analysts – 4/9/2026
- Neurogene price target lowered to $180 from $200 at Canaccord
- Buy Rating Backed by Strong NGN-401 Clinical Progress, De-Risking Efficacy Data, and Solid Cash Runway in Rett Syndrome
- Buy Rating Underpinned by De-Risked NGN‑401 Development, Aligned Manufacturing Strategy, and Cash Runway Through Key 2027–28 Catalysts